Screener
Arrowhead Research ARWR Q3 2026 earnings
Reported August 4, 2026 · After market close
Revenue$75.3MBeat by $31.1M
EPS-$1.36Miss by $0.08
Revenue estimate$44.2M
EPS estimate-$1.28
“We recently announced topline results from the SHASTA-3 and SHASTA-4 studies supporting our continued belief that plozasiran is a best-in-class molecule for patients with a spectrum of triglyceride disorders. Based on these promising results, we acquired a priority review voucher (PRV) that potentially accelerates the process of bringing this important new medicine to patients. On the commercial front, REDEMPLO continued to demonstrate growing momentum and penetration with physicians and patients with familial chylomicronemia syndrome. Lastly, we made strong progress across our broad pipeline of RNAi therapeutic candidates at various stages of development, expanding the opportunity to help patients in diverse disease areas.”
Next report
Nov 24, 2026 (in 2 months)Revenue estimate$59.4M
EPS estimate-$1.59
Valuation & ratios
Valuation
as of 09/17/26Versus estimates
Revenue
Diluted EPS
FAQ
- When did Arrowhead Research report Q3 2026 earnings?
- Arrowhead Research (ARWR) reported Q3 2026 earnings on August 4, 2026 after market close.
- What were Arrowhead Research's Q3 2026 revenue and EPS?
- Arrowhead Research reported revenue of $75.3M and eps of $-1.36 for Q3 2026.
- Did Arrowhead Research beat estimates in Q3 2026?
- Revenue beat the consensus estimate of $44.2M by $31.1M. EPS missed the consensus estimate of $-1.28 by $0.08.
- How did Arrowhead Research's Q3 2026 results compare year-over-year?
- Compared to the same quarter a year prior, revenue grew 171.0% from $27.8M a year earlier and eps declined 7.9% from $-1.26.
- Where can I find Arrowhead Research's Q3 2026 SEC filings?
- You can read the 8-K earnings release (0000879407-26-000058) and the 10-Q periodic report (0000879407-26-000057) directly on SEC EDGAR. The filing index links above go to sec.gov.
